Literature DB >> 10342699

Interpreting the decline in tuberculosis: the role of secular trends in effective contact.

E Vynnycky1, P E Fine.   

Abstract

BACKGROUND: The dramatic decline in tuberculosis (TB) in developed countries during the past century has been attributed to many factors, including improvements in living and social conditions and, more recently, effective treatment. Each of these changes should have reduced the average number of individuals 'effectively contacted' (i.e. sufficiently to transmit infection) by each infectious TB case.
METHOD: Estimates of the average number of individuals effectively contacted by each infectious TB case, for each year since 1900 in England and Wales, are derived as the ratio between published estimates of the annual risk of infection and estimates of the prevalence of infectious cases, as derived using a published model of the epidemiology of TB.
RESULTS: The results suggest that each infectious case contacted, on average, about 22 individuals in 1900 sufficiently to transmit Mycobacterium tuberculosis infection, and that this number declined to about 10 by 1950 and to approximately one by 1990.
CONCLUSIONS: Although several factors contributed to the decline in TB in developed countries during this century, a major contributor has been the decline in the number of effective contacts by each case over time. Similar declines have doubtless occurred over the past century for many infections in developed countries.

Entities:  

Mesh:

Year:  1999        PMID: 10342699     DOI: 10.1093/ije/28.2.327

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  30 in total

1.  The future of lung research in the UK.

Authors:  Stephen T Holgate
Journal:  Thorax       Date:  2007-12       Impact factor: 9.139

2.  Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis.

Authors:  Anthony T Fojo; Natalie L Stennis; Andrew S Azman; Emily A Kendall; Sourya Shrestha; Shama D Ahuja; David W Dowdy
Journal:  Lancet Public Health       Date:  2017-07

3.  Comparing Drivers and Dynamics of Tuberculosis in California, Florida, New York, and Texas.

Authors:  Sourya Shrestha; Andrew N Hill; Suzanne M Marks; David W Dowdy
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

4.  Representing Tuberculosis Transmission with Complex Contagion: An Agent-Based Simulation Modeling Approach.

Authors:  Erin D Zwick; Caitlin S Pepperell; Oguzhan Alagoz
Journal:  Med Decis Making       Date:  2021-04-27       Impact factor: 2.583

Review 5.  Tuberculosis vaccines and prevention of infection.

Authors:  Thomas R Hawn; Tracey A Day; Thomas J Scriba; Mark Hatherill; Willem A Hanekom; Thomas G Evans; Gavin J Churchyard; James G Kublin; Linda-Gail Bekker; Steven G Self
Journal:  Microbiol Mol Biol Rev       Date:  2014-12       Impact factor: 11.056

6.  Tuberculosis in Cape Town: An age-structured transmission model.

Authors:  Nello Blaser; Cindy Zahnd; Sabine Hermans; Luisa Salazar-Vizcaya; Janne Estill; Carl Morrow; Matthias Egger; Olivia Keiser; Robin Wood
Journal:  Epidemics       Date:  2015-10-20       Impact factor: 4.396

7.  Emergent heterogeneity in declining tuberculosis epidemics.

Authors:  Caroline Colijn; Ted Cohen; Megan Murray
Journal:  J Theor Biol       Date:  2007-04-27       Impact factor: 2.691

Review 8.  Protection against severe infectious disease in the past.

Authors:  Alexander Mercer
Journal:  Pathog Glob Health       Date:  2021-02-11       Impact factor: 2.894

9.  Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic.

Authors:  Robin Wood; Stephen D Lawn
Journal:  Curr HIV Res       Date:  2011-09       Impact factor: 1.581

10.  Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study.

Authors:  Hsien-Ho Lin; Megan Murray; Ted Cohen; Caroline Colijn; Majid Ezzati
Journal:  Lancet       Date:  2008-10-03       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.